Background: It is essential to interpret fine needle aspiration biopsy (FNAB) material correctly to create a common language among pathologists and surgeons, leading to a uniform approach to thyroid nodule management. We aimed to compare FNAB reports of patients at our institution who were treated with total thyroidectomy, before and after the Bethesda classification system. Patients and Methods: Patients who underwent total thyroidectomy for thyroid nodules are reviewed. 226 patients who underwent total thyroidectomy before the Bethesda era (2006-2009) were classified as Group-I, and 316 patients in whom total thyroidectomy was performed after the Bethesda classification system was introduced (2010-2014) were classified as Group-II. Results: Before Bethesda, ‘nondiagnostic' or ‘benign' lesions were reported in 16.4 and 45% of patients, respectively, which then significantly decreased to 4.7 and 32.9% as the Bethesda classification criteria came into use. In Group-II, the actual malignancy rates were 13.3, 2.8, 7.3, 15.5, 85.4, and 96.5% for Bethesda I, II, III, IV, V, and VI, respectively. Conclusion: Our experience confirms that the Bethesda classification system leads to a significant reduction in lesions that used to be reported as ‘benign' without compromising the actual rates of malignancy. It ensures better classification of so-called suspicious lesions, and allows for more accurate predictions of suspicious or malignant lesions.

Journal Section:
Original Article
Keywords:
Bethesda, Fine needle aspiration biopsy, Thyroid cancer, Total thyroidectomy
1.
Yassa L, Cibas ES, Benson CB, Frates MC, Doubilet PM, Gawande AA, Moore FD Jr, Kim BW, Nosé V, Marqusee E, Larsen PR, Alexander EK: Long-term assessment of a multidisciplinary approach to thyroid nodule diagnostic evaluation. Cancer 2007;111:508-516.
2.
Baloch ZW, LiVolsi VA, Asa SL, Rosai J, Merino MJ, Randolph G, Vielh P, DeMay RM, Sidawy MK, Frable WJ: Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute. Thyroid Fine-Needle Aspiration State of the Science Conference. Diagn Cytopathol 2008;36:425-437.
3.
Cibas ES, Ali SZ: The Bethesda System for Reporting Thyroid Cytopathology. Am J Clin Pathol 2009;132:658-665.
4.
Bongiovanni M, Spitale A, Faquin WC, Mazzucchelli L, Baloch ZW: The Bethesda System for Reporting Thyroid Cytopathology: a meta-analysis. Acta Cytol 2012;56:333-339.
5.
Lee K, Jung CK, Lee KY, Bae JS, Lim DJ, Jung SL: Application of Bethesda System for Reporting Thyroid Aspiration Cytology. Korean J Pathol 2010;44:521-527.
6.
Orija IB, Piñeyro M, Biscotti C, Reddy SS, Hamrahian AH: Value of repeating a nondiagnostic thyroid fine-needle aspiration biopsy. Endocr Pract 2007;13:735-742.
7.
Nagarkatti SS, Faquin WC, Lubitz CC, Garcia DM, Barbesino G, Ross DS, Hodin RA, Daniels GH, Parangi S: Management of thyroid nodules with atypical cytology on fine needle aspiration biopsy. Ann Surg Oncol 2013;20:60-65.
8.
Kim JW: The clinical significance of atypia in thyroid fine-needle aspiration. Eur Arch Otorhinolaryngol 2007;264:1053-1057.
9.
Harvey AM, Mody DR, Amrikachi M: Thyroid fine-needle aspiration reporting rates and outcomes before and after Bethesda implementation within a combined academic and community hospital system. Arch Pathol Lab Med 2013;137:1664-1668.
10.
Olson MT, Boonyaarunnate T, Altinboga AA, Ali SZ: ‘Suspicious for papillary thyroid carcinoma' before and after the Bethesda System for Reporting Thyroid Cytopathology: impact of standardized terminology. Acta Cytol 2014;58:15-22.
11.
Chen JC, Pace SC, Chen BA, Khiyami A, McHenry CR: Yield of repeat fine-needle aspiration biopsy and rate of malignancy in patients with atypia or follicular lesion of undetermined significance: the impact of the Bethesda System for Reporting Thyroid Cytopathology. Surgery 2012;152:1037-1044.
12.
Gürkan Dumlu E, Kiyak G, Bozkurt B, Tokaç M, Polat B, Cakir B, Güler G, Kiliç M: Correlation of thyroid fine-needle aspiration with final histopathology: a case series. Minerva Chir 2013;68:191-197.
13.
Alabdulqader NA, Shareef SQ, Ali JA, Yousef MM, Al-Abbadi MA: Application of the Bethesda System for Reporting Thyroid Cytopathology in the Eastern Province of Saudi Arabia: a follow-up study. Acta Cytol 2015;59:233-238.
14.
Sullivan PS, Hirschowitz SL, Fung PC, Apple SK: The impact of atypia/follicular lesion of undetermined significance and repeat fine-needle aspiration: 5 years before and after implementation of the Bethesda System. Cancer Cytopathol 2014;122:866-872.
15.
Srbova L, Gabalec F, Ryska A, Cap J: Results of retrospective classification of thyroid FNAs according to the Bethesda system: would this have improved accuracy? Cytopathology 2015;26:231-237.
16.
Kapila K, Qadan L, Ali RH, Jaragh M, George SS, Haji BE: The Bethesda System for Reporting Thyroid Fine-Needle Aspiration Cytology: a Kuwaiti experience - a cytohistopathological study of 374 cases. Acta Cytol 2015;59:133-138.
© 2017 S. Karger GmbH, Freiburg
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2017
You do not currently have access to this content.